Family Dollar Stores (FDO) recently warned that earnings would decline in fiscal 2014 compared with the prior year as the retail environment remained challenging. This Zacks Rank #5 (Strong Sell) is facing tough market conditions as its core customers who shop for value haven’t seen the benefits of the economic recovery. Family Dollar is a discount retailer operating 8,000 stores in rural and urban locations in 46 states.
Lackluster First QuarterOn Jan 9, Family Dollar reported fiscal first quarter 2014 results which missed the Zacks Consensus Estimate by a penny. Sales rose 3.2% to $2.5 billion from $2.4 billion in the year ago period. This was in line with its previously announced guidance for the quarter.
Top 10 International Companies For 2015: Mast Therapeutics Inc (MSTX)
Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., incorporated in December 1995, is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.
ANX-188 (purified poloxamer 188)
ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188 (P1880, is a nonionic, block copolymer that has been found to improve microvascular blood flow by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces. The Company�� purified form of P188 (purified P188), which is the active ingredient in ANX-188, was designed to eliminate certain low molecular weight substances present in P188 (non-purified), which is primarily responsible for the moderate to moderately severe elevations in serum creatinine levels (acute renal dysfunction) observed in prior clinical studies of P188 (non-purified). Purified P188 has been evaluated in multiple clinical studies by a prior sponsor, including a 255-patient, phase III study.
ANX-514 (docetaxel for injectable emulsion)
ANX-514 is a detergent-free emulsion formulation of docetaxel, an intravenously-injected chemotherapy drug commonly used to treat solid tumors. Taxotere, a branded form! ulation of docetaxel, is approved to treat breast, non-small cell lung, prostate, gastric, and head and neck cancers. ANX-514 was designed to have clinically comparable release of docetaxel relative to Taxotere while eliminating the presence of polysorbate 80 and ethanol, both of which are used to solubilize docetaxel in the Taxotere formulation. The ANX-514 formulation solubilizes docetaxel using oil droplets consists of a combination of non-toxic excipients. Docetaxel is contained within these oil droplets and can be administered intravenously without using detergents as pharmaceutical vehicles. Once in central circulation, the emulsion is metabolized rapidly, leaving chemically-identical active ingredient to exert its cytotoxic effect. ANX-514 may reduce the incidence and severity of hypersensitivity reactions and delay the onset of fluid retention.
Exelbine (vinorelbine injectable emulsion)
Exelbine is an emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the United States to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.
In August 2011, the Company received a complete response letter from the Food and Drug Administration (FDA) stating that it could not approve the Exelbine Non Disclosure Agreement (NDA) in its present form and that the bioequivalence study would need to be repeated because the authenticity of the drug products used in the bioequivalence trial could not be verified in accordance with FDA standards. However, the Company elected to discontinue independent development of Exelbine and as of December 31, 2011, the Company was seeking a partner or outside investor for the program to complete the necessary bioequivalence study.
The Company competes with GlaxoSmithKline, Provenge and Pfizer.
Advisors' Opinion:- [By James E. Brumley]
A little over a month ago, owning Mast Therapeutics, Inc. (NYSE: MSTX) was nothing but pure misery. Shares plunged from $0.63 to $0.43 in one day, when details of a dilutive public offering were unveiled. As is so often the case though, the market may have overshot with the selling effort that KO's MSTX. Though putting more shares 'out there' mathematically meant existing shareholders would have to share more of the company's upside with newcomers, what's slowly coming to light is that the inflow of new cash is still more advantageous to those prior shareholders; the company would progress little without it.
- [By Lauren Pollock]
Mast Therapeutics Inc.(MSTX) said the U.S. Food and Drug Administration gave orphan-drug designation to its MST-188 drug for the treatment of acute limb ischemia, providing a boost for the biopharmaceutical firm. Shares surged.
- [By Roberto Pedone]
Mast Therapeutics (MSTX), a biopharmaceutical company, focuses on developing therapies for serious or life-threatening diseases. This stock closed up 2.1% 65 cents per share in Thursday's trading session.
Thursday's Range: $0.63-$0.67
52-Week Range: $0.40-$1.10
Thursday's Volume: 1.11 million
Three-Month Average Volume: 1.88 millionFrom a technical perspective, MSTX spiked modestly higher here right above its 50-day moving average of 61 cents per share with decent upside volume. This stock has been trending sideways and consolidating for the last month, with shares moving between 60 cents on the downside and 72 cents on the upside. Shares of MSTX are now starting to push higher and into range of triggering a big breakout trade above the upper-end of its recent sideways trading chart pattern. That trade will hit if MSTX manages to clear some near-term overhead resistance levels at 68 to 72 cents per share with high volume.
Traders should now look for long-biased trades in MSTX as long as it's trending above some key near-term support at 60 cents per share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.88 million shares. If that breakout materializes soon, then MSTX will set up to re-test or possibly take out its next major overhead resistance levels at 80 to 85 cents per share, or even 93 cents per share.
Top 5 Managed Healthcare Companies To Invest In Right Now: Kiwibox.com Inc (KIWB)
Kiwibox.Com, Inc. (Kiwibox), incorporated on April 19, 1988, is an early stage company. The Company owns and operates Kiwibox.com, which is a social networking Website. The Company has equipped the Website with the advertising features, which enable sponsors to self-direct their message to specific target audiences based on gender, age, geographic region, education, and interests. As of December 31, 2011, the Company generated the majority of its revenue from advertising/sponsorships. On September 30, 2011 Kiwibox.com acquired 100% interests in the social network, KWICK!! Community GmbH & Co. KG, and interest of its general partner, Kwick!! Community Beteiligungs GMBH. On March 7, 2011 the Company acquired Pixunity.DE a German photo book community.
Kiwibox.com has developed a monitoring model. The Kiwibox.com platform is equipped with technology features, which includes the private sphere configuration of users, contact blocs, anti-spam protection and intelligent self-learning user-scoring feature.
The Company competes with Facebook.com, Twitter and MySpace.com.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap stocks Kiwibox.com Inc (OTCMKTS: KIWB), Eyes on The Go Inc (OTCMKTS: AXCG) and Green Endeavors Inc (OTCMKTS: GRNE) were sinking 37.5%, 28.57% and 23.9%, respectively. Moreover, it should be mentioned that all three small cap stocks have been the subject of recent paid promotions or investor relation campaigns which have gotten them mentions in various investment newsletters or investor alerts. So are the promotional or investor relation campaigns over with for these three small caps? Here is a quick look to help you decide:
Kiwibox.com Inc (OTCMKTS: KIWB) Makes an Acquisition in Germany and Reports Surging RegistrationsSmall cap Kiwibox.com Inc owns and operates social networking sites like Kiwibox.com, a site that has over over 14 years experience as social network. On Friday, Kiwibox.com Inc sank 37.5% to $0.005 for a market cap of $3.41 million plus KIWB is down 58.3% over the past year and down 63% over the past five years according to Google Finance.
Top 5 Managed Healthcare Companies To Invest In Right Now: Bayer AG (BAYRY)
Bayer AG is a management holding company. The Company�� business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals. Bayer CropScience is engaged in the crop protection and non-agricultural pest control. Bayer MaterialScience supplies polymers, and develops solution for a range of applications. In November 2009, Bayer MaterialScience acquired the polymer coatings business from Lombard Medical Technologies PLC. On November 2, 2009, it acquired Athenix Corporation. On October 1, 2009, it acquired two dermatology product lines from SkinMedica, Inc., Carlsbad, California, United States. On June 25, 2009, it acquired the remaining 10% interest in Bayer Polymers (Shanghai) Co. Ltd., China. In May 2009, it acquired the remaining 49% interest in Berlimed, s.a., Spain, from Juste s.a. Quimica Farmac茅utica (Juste), and in return sold its 51% interest of Justesa Imagen, s.a., Spain, to Juste. In May 2009, it also sold the Thermoplastics Testing Center, Krefeld, Germany, to Underwriters Laboratories Inc. In March 2010, the Company announced that its Bayer MaterialScience LLC has acquired Artificial Muscle, Inc, a company active in electroactive polymers for the consumer electronics industry.
Bayer HealthCare
The Company researches, develops, manufactures pharmaceutical and medical products. Bayer HealthCare operates in four operating divisions: Animal Health, which is engaged in manufacture of veterinary medicines and grooming products; Bayer Schering Pharma, which is engaged in manufacture of prescription medicines; Consumer Care, which is engaged in the manufacture of over-the-counter medicines and dietary supplements, and Medical Care, which is engaged in manufacture of blood glucose monitoring devices and contrast agent injecti! on systems. Its products for farm animals include Baytril. Its products for companion animals include Advantage/Advantix and Baytril. Its drug discovery in the pharmaceuticals segment focuses on the areas of cardiology, oncology,
women�� healthcare and diagnostic imaging.
Bayer CropScience
CropScience maintains a global network of research and development facilities. In the Crop Protection segment it identifies and develops safe and economically sustainable insecticides, fungicides and herbicides and carries its research projects in areas, such as plant health or stress tolerance. As of December 31, 2009, its active ingredient pipeline of Crop Protection contained 20 development projects, of which 10 was at an advanced stage and 10 at an early stage of development, and an additional 45 projects was undergoing early-stage research. Its operations are structured into six business operations units: four regional Crop Protection units plus the Environmental Science and BioScience units. Its insecticides include Confidor/ Admire, Calypso, Decis, Temik and Oberon. Its fungicides include Antracol, Fandango, Flint/Stratego/Sphere/Twist, Folicur and Previcur Energy. Its herbicides include Atlantis, Basta, Betanal, Fenikan, Hoestar, Husar, MaisTer, Puma. Its seed treatment products include Bariton, Gaucho, Lamarador, Poncho and Raxil.
Bayer MaterialScience
The Company supplies materials, such as polycarbonates and polyurethanes and system solutions for a range of everyday uses. It operates in three business units: Polyurethanes, Polycarbonates, and Coatings, Adhesives and Specialties. Its Coatings, Adhesives, Specialties producst include Desmodur, Bayhydur, Dispercoll and Artwalk. Its Polycarbonates include Makrolon, Makrofol / Bayfol, Fantasia and Bayblend. Its Polyurethanes include Multitec, Baydur, Bayflex, Baypreg and Vulkollan. Its Thermoplastic Polyurethanes include Desmopan / Texin.
Advisors' Opinion:- [By Sean Williams]
Another big beneficiary from type 1 diabetes is glucose-monitoring device makers. Perhaps the most exciting product in this space is Bayer's (NASDAQOTH: BAYRY ) Contour Next Link. Bayer has partnered its device with Medtronic (NYSE: MDT ) in such a way that it'll connect wirelessly to Medtronic's insulin pump, drastically reducing many instances of human error or forgetfulness, and delivering the right dosage of insulin to patients throughout the course of the day.
Top 5 Managed Healthcare Companies To Invest In Right Now: Companhia Energetica de Minas Gerais Cemig (CIG)
Companhia Energetica de Minas Gerais (CEMIG), incorporated on May 22, 1952, is a Brazil-based holding company mainly engaged in the generation, transmission and distribution of electricity. In the generation segment, CEMIG operates through hydroelectric plants, thermoelectric plants and wind farms. In the transmission segment, as of December 31, 2008, CEMIG�� transmission network was comprised of 38 substations with a total of 94 transformers and an aggregate transformation capacity of 15,583 Megavolt amperes. In the distribution business, as of December 31, 2008, the Company owned and operated 451,539 kilometers of distribution lines, supplying electricity to approximately 10 million customers. CEMIG is also engaged in the natural gas distribution business in Minas Gerais, through its subsidiary Companhia de Gas de Minas Gerais - GASMIG, as well as in the telecommunications business, through its subsidiary Cemig Telecomunicacoes SA - Cemig Telecom, which provides optical fiber and coaxial cable network.
Power Generation and Trading
As of December 31, 2009, the Company generated electricity at 54 hydroelectric plants, three thermoelectric plants and two wind farms, and had a total installed capacity of 6,624 megawatts. As of December 31, 2009, it owned and operated 3,085 miles of transmission lines and 281,756 miles of distribution lines. It holds concessions to distribute electricity in 96.7% of the territory of Minas Gerais. Eight of CEMIG�� hydroelectric plants accounted for approximately 81% of its installed electric generation capacity during the year ended December 31, 2009. CEMIG operates the Ipatinga thermoelectric plant, through its subsidiary Usina Termica Ipatinga S.A. The plant has an installed capacity of 40 megawatts, generated by two units and that uses blast furnace gas as fuel. The Company operates the Sa Carvalho hydroelectric power plant, located on the Piracicaba River in the municipality of Antonio Dias in the State of Minas Gerais, through its subsid! iary Sa Carvalho S.A. The Company�� Rosal hydroelectric plant has an installed capacity of 55 megawatts. The Rosal plant is located on the Itabapoana River, which runs along the border between the states of Espirito Santo and Rio de Janeiro.
Cemig Capim Branco Energia S.A. is engaged in developing the Capim Branco Generating Complex in partnership with Companhia Vale do Rio Doce (CVRD), a mining company, Comercial e Agricola Paineiras, an agricultural company, and Companhia Mineira de Metais (CMM) a metallurgical company. Horizontes Energia S.A. was formed by the Company to generate and trade electricity, through the commercial operation of its hydroelectric plants: the Machado Mineiro Power Plant (located on the Pardo River in the municipality of Ninheira in the State of Minas Gerais with an installed capacity of 1.72 megawatts); the Salto do Paraopeba Power Plant (located on the Paraopeba River in the town of Jeceaba in the State of Minas Gerais with an installed capacity of 2.37 megawatts); the Salto Voltao Power Plant (located on the Chapecozinho River in the town of Xanxere in the State of Santa Catarina with an installed capacity of 8.2 megawatts), and the Salto do Passo Velho Power Plant (located on the Chapecozinho River in the town of Xanxere in the State of Santa Catarina with an installed capacity of 1.8 megawatts), as well as other generating projects.
Usina Termeletrica Barreiro S.A. holds the assets of the Barreiro thermoelectric power plant. The Irape Hydroelectric Power Plant, which has an installed capacity of 360 megawatts, is located on the Jequitinhonha River, in northern Minas Gerais. The Company�� wind farm, Morro do Camelinho is located in Gouveia, a municipality in northern Minas Gerais. It has a total generation capacity of 1 megawatt, powered by four turbines with a capacity of 250 kilowatts each. Central Eolica Praia do Morgado S.A is located in the county of Acarau, in the State of Ceara. Central Eolica Volta do Rio S.A is located in the county ! of Acarau! , in the State of Ceara.
Transmission
The Company�� transmission business consists of the bulk transfer of electricity from the power plants where it is generated to the distribution system, which carries the electricity to final consumers, and others consumer agents connected directly in the transmission grid. Its transmission system comprises transmission lines and step-down substations with voltages ranging from 230 kilovolt to 500 kilovolt. As of December 31, 2009, the Company�� transmission network in Minas Gerais consisted of 1,352 miles of 500 kilovolt lines, 1,244 miles of 345 kilovolt lines and 485 miles of 230 kilovolt lines, as well as 35 substations with a total of 94 transformers and an aggregate transformation capacity of 15,506 megavolt ampere. The Company transmits the energy that it generates and the energy that it purchases from Itaipu and other sources, as well as the energy for the interconnected power system. On December 31, 2009, the Company also had 13 industrial consumers, to whom it transported 4,103 gigawatt hour directly with high voltage energy, through their connections to its transmission lines. Nine of these industrial consumers accounted for approximately 66.9% of the transported total volume of electricity. The Company also transmits energy to distribution systems, through the south/southeast-linked system of the grid.
Distribution and Purchase of Electric Power
The Company�� distribution operation consists of electricity transfers from distribution substations to final consumers. Its distribution network consists of a network of overhead and underground lines and substations with voltages lower than 230 kilovolts. The Company supplies electricity to industrial consumers at the higher end of the voltage range and residential and commercial consumers at the lower end of the range.
Other Businesses
The Company holds approximately 55% of Gasmig and Petrobras, through its subsidiary, Gaspet! ro-Petrob! ras Gas S.A., holds 40%. In 2009, Gasmig supplied approximately 1.5 million cubic meters of natural gas per day to 276 consumers, including 175 industrial and commercial clients, 93 retail distribution stations for natural gas vehicles, two thermal power plants and six distributors of compressed natural gas (CNG). Gasmig supplied 0.2 million cubic meters of gas per day to thermal power plants and 1.3 million cubic meters of gas per day to retail consumers. In addition to, Gasmig also supplied eight customers with re-gasified liquefied natural gas (LNG). In 2009, Gasmig distributed approximately 4.1% of all natural gas distributed in Brazil.
The Company�� owns a 99.9% interest in Cemig Telecomunicacoes S.A., which has an optical fiber-based long-distance communications backbone installed along the Company�� power grid using optical ground wire cables. This communications backbone is connected to an access network that is based on hybrid fiber-coaxial cable technology and is deployed along its power grid. The telecommunication services provided by Cemig Telecomunicacoes S.A., through its network are signal transportation and access, both for point-to-point and point-to-multipoint applications, delivered to telecommunications operators and Internet service providers on a channel basis. Cemig Telecomunicacoes S.A. also provides intra-company data transmission services to the Company. CEMIG provides consulting services to governments and public utility companies in the electricity industry. The Company has a 100% interest in Efficientia S.A.
Advisors' Opinion:- [By Jon C. Ogg]
Companhia Energ茅tica de Minas Gerais S.A. (NYSE: CIG) is a top utility in Brazil. It even trades over 3 million shares on average in New York. At $5.70, the 52-week range is $5.48 to $8.89. This ADR is down about 4% so far in 2014.
- [By David Dittman]
Question: CEMIG (NYSE: CIG) is still way off multi-year highs due to some pretty serious government interference in Brazil. Nevertheless, it’s up dramatically the last couple of months.
- [By Garrett Cook]
Toward the end of trading Friday, the Dow traded down 0.60 percent to 16,947.43 while the NASDAQ declined 0.75 percent to 4,557.59. The S&P also fell, dropping 0.83 percent to 1,980.97.
Leading and Lagging Sectors Cyclical consumer goods & services shares fell by just 0.50 percent in trading on Friday. Top gainers in the sector included ULTA Salon, Cosmetics & Fragrance NASDAQ: (ULTA), up 17.5 percent, and 1-800-Flowers.com (NASDAQ: FLWS), up 4.5 percent. In trading on Friday, utilities shares were relative laggards, down on the day by about 1.89 percent. Meanwhile, top decliners in the sector included Companhia Energética de Minas Gerais - CEMIG (NYSE: CIG), down 4.7 percent, and CPFL Energia SA (NYSE: CPL), off 4.3 percent. Top Headline Darden Restaurants (NYSE: DRI) reported better-than-expected fiscal first quarter earnings. The Orlando, Florida-based company reported a quarterly loss of $19.3 million, or $0.14 per share, versus a year-ago profit of $42.2 million, or $0.32 per share. Excluding non-recurring items, the company earned $0.32 per share. Its sales surged to $1.6 billion versus $1.53 billion. However, analysts were expecting earnings of $0.30 per share on revenue of $1.6 billion. Equities Trading UP Conversant (NASDAQ: CNVR) shares shot up 30.25 percent to $34.79 after Alliance Data Systems (NYSE: ADS) announced its plans to buy Conversant for $35 per share. Shares of ULTA Salon, Cosmetics & Fragrance (NASDAQ: ULTA) got a boost, shooting up 17.69 percent to $114.72 after the company reported upbeat second-quarter results and raised its outlook. The company also unveiled a five-year plan for impressive growth. Sportsman's Warehouse Holdings (NASDAQ: SPWH) shares were also up, gaining 15.89 percent to $7.00 after the company reported stronger-than-expected fiscal second-quarter results. Equities Trading DOWN Shares of Ruckus Wireless (NASDAQ: RKUS) were down 5.19 percent to $14.35. Buckingham
No comments:
Post a Comment